Vitamin D-Dependent Rickets Type 2A (VDDR2A) — Comprehensive Research Report

1. Disease Information

Overview. Vitamin D-dependent rickets type 2A (VDDR2A), also widely known as hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) or hereditary vitamin D-resistant rickets, is a rare autosomal recessive Mendelian disorder caused by biallelic loss-of-function mutations in the vitamin D receptor gene (VDR), producing end-organ resistance to the active vitamin D hormone, 1,25-dihydroxyvitamin D₃ (calcitriol), rather than a defect in vitamin D synthesis itself. Unlike nutritional rickets or VDDR type 1 (a biosynthetic enzyme defect), VDDR2A patients have normal or elevated circulating 1,25(OH)₂D levels but the target tissues cannot respond to it (OMIM #277440; NORD).

Key identifiers: - OMIM: #277440 (VDDR2A); causal gene VDR, OMIM 601769 (OMIM 277440; OMIM 601769) - Gene: VDR, chromosome 12q13.11 - GTR/MedGen concept: "Vitamin D-dependent rickets, type II" and "…type II with alopecia" are indexed as related concepts (NIH GTR C3536983; NIH GTR C0342646) - Orphanet: grouped under "Hypocalcemic vitamin D-dependent rickets" (Orphanet) - Suggested MONDO* term: hereditary vitamin D-resistant rickets (VDDR2A subtype) — confirm exact MONDO CURIE against the local MONDO adapter before curation.

Synonyms/alternative names: Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR); vitamin D receptor deficiency rickets; hereditary hypocalcemic vitamin D-resistant rickets; pseudo-vitamin D deficiency rickets type II; hereditary vitamin D-resistant rickets with alopecia (when alopecia present).

Evidence base: Almost all published knowledge derives from individual patient case reports and small case series (often single kindreds), supplemented by two published retrospective single-center cohorts (a Saudi Arabian series and Chinese/Egyptian family series), rather than large aggregated disease-level registries — reflecting the disorder's extreme rarity. Suggested-evidence sources: HUMAN_CLINICAL (predominant), supplemented by MODEL_ORGANISM (VDR-null mouse/rat) and IN_VITRO (transfection/reporter assays of mutant VDR function).

2. Etiology

Disease causal factor: VDDR2A is caused by biallelic (typically homozygous or compound heterozygous) loss-of-function mutations in VDR on chromosome 12q13.11, encoding the nuclear vitamin D receptor. This is a purely genetic/Mendelian etiology — no environmental or infectious trigger is causal, though vitamin D intake/sunlight exposure modulates severity of the biochemical phenotype.

Genetic risk factors: - Consanguinity is a major risk factor given the autosomal recessive inheritance and the disease's concentration in consanguineous kindreds (Chinese, Egyptian, Middle Eastern, and Saudi Arabian case series predominate in the literature) (PMC4589239; PubMed 24859502). - Uniparental disomy of chromosome 12 has been documented as a distinct mechanism producing apparent homozygosity for a VDR mutation without both parents being carriers — confirmed by SNP array in at least one reported case (PLOS ONE / PMC4496068). - A dominant-negative mechanism has also been reported: a single mutant VDR allele with a constitutive corepressor (NCoR) interaction and ligand-independent VDRE binding causes dominantly inherited HVDRR, analogous to dominant-negative thyroid hormone receptor mutations (ScienceDirect / PMC5365159; PubMed 28377956). A 2025 case report also described an atypical heterozygous VDDR2A presentation (c.146+9dup) presenting with pseudoarthrosis rather than the classic recessive picture (Goldberg et al. 2025, Case Reports in Endocrinology; PMC12003035).

Environmental risk factors: None are causal, but low ambient sunlight/dietary vitamin D deficiency can exacerbate the biochemical/clinical phenotype in an already receptor-resistant patient by lowering the (already ineffective) precursor pool further, and can complicate diagnosis by mimicking nutritional rickets.

Protective factors: No specific protective genetic variant is described. Adequate dietary calcium intake mitigates (but does not cure) the phenotype, since the downstream defect is receptor unresponsiveness rather than calcium/vitamin D substrate availability — this underlies the calcium-based (rather than vitamin D-based) treatment strategy (see §12).

Gene-environment interaction: The core interaction is that the severity of clinical rickets/hypocalcemia is buffered by dietary calcium intake independent of VDR/calcitriol signaling — i.e., sufficiently high oral or IV calcium can partially bypass the VDR defect by driving passive, non-VDR-mediated paracellular intestinal calcium absorption.

3. Phenotypes

VDDR2A phenotypes fall into rickets/mineral-metabolism findings (present in essentially all patients) and alopecia (present in a majority but not universal, and correlating with mutation severity).

Onset and course: Manifestations typically present in infancy to early childhood (rickets is usually evident by the first 1–2 years of life; alopecia, when present, is often noted from birth or shortly thereafter). Severity is variable — even within families with the same genotype — and disease course is generally described as an early, severe, and treatment-resistant rachitic picture that improves with high-dose calcium repletion (see §12) but with alopecia typically not reversing.

Alopecia frequency and severity correlation: Reported figures vary by cohort, from roughly half to the majority of patients: "most patients have total alopecia in addition to rickets" (OMIM 277440) and "approximately 80% of patients with HVDRR have early-onset alopecia... the degree of alopecia is associated with the severity of the vitamin D resistance," with an unusual patchy pattern of total baldness adjacent to normal or scant hair (PMC3196847). Alopecia is a poor prognostic marker for treatment response (see §12).

Atypical presentations: VDDR2A can present with hypophosphatemia in the absence of hypocalcemia, causing initial misclassification as an FGF23-mediated hypophosphatemic rickets (JCEM Case Reports, PMC/Oxford; Karger/PMC12187100) — an important differential-diagnosis pitfall (§10).

Quality of life impact: Untreated or delayed-diagnosis disease causes significant motor disability (inability to bear weight/walk due to bone pain and deformity) that reverses substantially with calcium therapy (documented improvement from non-ambulatory to independent walking within weeks of IV calcium in case reports); alopecia carries a persistent psychosocial/cosmetic burden since it is typically treatment-refractory.

4. Genetic/Molecular Information

Causal gene: VDR (Vitamin D Receptor), OMIM *601769, chromosome 12q13.11 (GeneCards; OMIM 601769).

Variant spectrum: VDDR2A is caused by heterogeneous loss-of-function mutations distributed across the DNA-binding domain (DBD) and ligand-binding domain (LBD) of VDR, including: - Missense mutations disrupting ligand binding or DNA binding — e.g., I268T (LBD, ~5–10-fold reduced 1,25(OH)₂D₃ affinity, ~65-fold higher concentration required for equipotent transactivation) (PubMed 15308610); V26M (DBD, impairs DNA binding) (PMC2794978); R343H and R343C (recently reported, associated with alopecia and with a hypophosphatemia-predominant presentation respectively) (PMC5681508; JCEM Case Reports 2024). - Splice-site mutations — e.g., a novel splice-site mutation successfully managed with oral calcium therapy (ScienceDirect); a 2025 case with a heterozygous c.146+9dup splice-region variant with an atypical pseudoarthrosis presentation (PMC12003035). - Compound heterozygous genotypes are well documented, including in a 2008 report of compound heterozygous VDR mutations with alopecia (PubMed 19049339) and a 2025 congress report of a novel compound-heterozygous VDR mutation (Endocrine Abstracts 2025). - Uniparental disomy of chromosome 12, producing homozygosity for a maternal-only VDR mutation despite the father not being a carrier (PMC4496068). - Rare dominant-negative heterozygous mutations producing HVDRR via constitutive corepressor (NCoR) recruitment (PMC5365159).

Variant classification/functional consequence: The great majority are classified functionally as loss-of-function (complete or partial) via in-vitro transactivation/reporter assays; a minority display dominant-negative behavior. Standard ACMG/AMP pathogenicity classification should be applied per-variant via ClinVar; no single recurrent "hot-spot" variant dominates worldwide — mutations are largely private/family-specific, consistent with a rare, ethnically dispersed autosomal recessive disorder.

Allele frequency: Given the rarity and largely private nature of pathogenic VDR loss-of-function alleles, population database (gnomAD) frequencies for individual pathogenic variants are expected to be near-absent/singleton; no common founder allele with an appreciable population allele frequency has been established in the literature surveyed.

Somatic vs. germline: VDDR2A is exclusively a germline Mendelian disorder (not somatic/acquired).

Modifier genes: None firmly established; phenotypic variability (notably in alopecia severity) is attributed to the specific functional consequence of the causal VDR allele (LBD vs. DBD, partial vs. complete loss of function, dominant-negative vs. simple loss-of-function) rather than a distinct modifier locus.

Suggested GO terms for the VDR molecular function/pathway: GO:0004879 (nuclear receptor activity), GO:0070644 (vitamin D response element binding), GO:0008202 (steroid metabolic process), GO:0060348 (bone development).

5. Environmental Information

Because VDDR2A is a fully penetrant genetic receptor defect, environmental factors do not cause the disease but strongly modulate symptom severity and diagnostic presentation: - Dietary vitamin D/calcium intake and sunlight exposure affect substrate availability but cannot correct receptor unresponsiveness; low dietary calcium can precipitate more severe hypocalcemic crises (seizures/tetany) in an affected infant. - No infectious agent is implicated in VDDR2A pathogenesis. - No specific toxin/occupational exposure is implicated (this is a congenital, not acquired, receptor defect).

6. Mechanism / Pathophysiology

Molecular pathway. VDR is a member of the nuclear hormone receptor superfamily. Upon binding its ligand, 1,25-dihydroxyvitamin D₃ (calcitriol), the liganded VDR heterodimerizes with the retinoid X receptor (RXR). Helix 12 (H12) of the VDR ligand-binding domain acts as a flexible "lid" whose ligand-induced repositioning creates the activation function-2 (AF-2) hydrophobic cleft required for coactivator recruitment; RXR undergoes an allosteric "phantom ligand effect" shift toward an active conformation even without its own ligand (Oxford Mol Endocrinol; PMC3087838). The VDR-RXR heterodimer binds vitamin D response elements (VDREs) — direct repeats of the RGKTSA hexameric half-site separated by 3 nucleotides (DR3 motif) — in enhancer regions of target genes, recruiting a multiprotein complex (pioneer factors, chromatin remodelers, coactivators, Mediator complex) that docks onto RNA polymerase II to drive transcription of vitamin D target genes (e.g., intestinal calcium transporters, renal calcium-handling genes, osteoblast genes) (search synthesis of ScienceDirect VDRE overview, PMC6332450).

Causal chain — genetic lesion to clinical phenotype: 1. Biallelic (or dominant-negative) VDR mutation → loss of ligand binding (LBD mutations, e.g. I268T) or loss of DNA binding (DBD mutations, e.g. V26M) → impaired or absent VDR-RXR-VDRE transcriptional activation of calcitriol target genes. 2. End-organ (intestinal, renal, skeletal) resistance to 1,25(OH)₂D₃ → decreased active intestinal calcium (and secondarily phosphate) absorption despite normal or compensatorily elevated circulating calcitriol. 3. Hypocalcemia → secondary/compensatory hyperparathyroidism (elevated PTH) → renal phosphate wasting exacerbating hypophosphatemia; PTH-driven bone resorption contributes to elevated alkaline phosphatase. 4. Combined hypocalcemia/hypophosphatemia → defective mineralization of osteoid at growth plates and bone matrix → rickets/osteomalacia, growth retardation, bone pain/deformity, muscle weakness (mineral-dependent neuromuscular function). 5. Independently (not calcium-pathway mediated): VDR loss in hair-follicle keratinocytes disrupts a ligand-independent VDR function required for postmorphogenic anagen (growth phase) initiation of the hair cycle, causing alopecia — this occurs even though the alopecia-causing VDR function does not require 1,25(OH)₂D binding, explaining why alopecic patients are especially treatment-refractory to vitamin D/calcitriol-based therapy while their rickets can still be treated via calcium (see below and §12) (JCI 11676; Oxford Mol Endocrinol 19(4):855; PMC11720424).

Cellular processes involved: Intestinal enterocyte calcium transport (TRPV6/calbindin-mediated active transport, normally VDR-induced); osteoblast/osteoclast coupling and PTH-driven bone remodeling; parathyroid chief cell PTH secretion (normally suppressed by calcitriol-VDR signaling — loss of this suppression contributes to the hyperparathyroidism); hair-follicle keratinocyte stem-cell-driven anagen re-entry (VDR-dependent, ligand-independent, involving cooperative β-catenin/Lef1 canonical Wnt signaling that is abolished in VDR-null keratinocytes) (PNAS 0702884104).

Biochemical abnormalities: Hypocalcemia, hypophosphatemia (variable — can be absent in some presentations), elevated alkaline phosphatase, elevated PTH, and the biochemically distinguishing feature of markedly elevated (not low) circulating 1,25(OH)₂D, which differentiates VDDR2A from VDDR1A (CYP27B1 biosynthetic defect, where 1,25(OH)₂D is low).

Suggested GO/biological process terms: GO:0070508 (cholesterol import)-adjacent calcium pathway terms are less relevant; more directly: GO:0006816 (calcium ion transport), GO:0070508 n/a, GO:0060349 (bone morphogenesis), GO:0042633 (hair cycle), GO:0022416 (chaeta development)-adjacent is not applicable to humans — use GO:0042633 (hair cycle) and GO:0030855 (epithelial cell differentiation) for the alopecia arm.

Suggested CL (cell type) terms: CL:0000584 (enterocyte), CL:0000062 (osteoblast), CL:0000092 (osteoclast), CL:0000446 (parathyroid chief cell), CL:0000312 (keratinocyte), CL:0002337 (hair follicle stem cell / bulge keratinocyte).

Model system / omics data: The literature surveyed is predominantly clinical case reports and targeted functional (reporter-gene transactivation) assays of specific VDR mutants; no large-scale transcriptomic/proteomic/single-cell dataset specific to human VDDR2A patient tissue was identified in this search. Model-organism transcriptomic characterization exists for VDR-null mice (see §15).

7. Anatomical Structures Affected

Organ level: - Primary: Skeletal system (long bones, growth plates, ribs — costochondral junctions), skin/hair follicles. - Secondary: Parathyroid glands (secondary hyperparathyroidism), kidney (secondary renal phosphate wasting via PTH), skeletal muscle (hypotonia/weakness), teeth (enamel defects). - Body systems: Musculoskeletal, endocrine, integumentary; less so cardiovascular/neurological (hypocalcemic seizures reflect a neuromuscular/CNS excitability consequence of the mineral disturbance rather than primary CNS pathology).

Tissue/cell level: Growth-plate chondrocytes and osteoid-forming osteoblasts (impaired mineralization); intestinal enterocytes (impaired active transcellular calcium absorption); renal tubular epithelium (secondary phosphate handling); hair follicle keratinocytes, specifically the bulge stem cell niche, which forms normally in VDR-null models but fails to regenerate the lower hair follicle without VDR (PNAS 0702884104).

Subcellular level: VDR is a nuclear receptor; the defect is localized to nuclear transcriptional machinery (GO Cellular Component: GO:0005634 nucleus; GO:0090575 RNA polymerase II transcription regulator complex) rather than membrane, mitochondrial, or lysosomal compartments.

Localization/laterality: Systemic/bilateral, symmetric — skeletal changes affect long bones bilaterally (e.g., bilateral genu varum), and alopecia, when present, is typically diffuse/total rather than a focal or lateralized process.

Suggested UBERON terms: UBERON:0002481 (bone tissue), UBERON:0002049 (vasculature)-not primary, UBERON:0000014 (zone of skin), UBERON:0002073 (hair follicle), UBERON:0001103 (diaphragm)-n/a; more precisely UBERON:0002365 (exocrine gland)-n/a — best fits: UBERON:0001474 (bone element), UBERON:0002073 (hair follicle), UBERON:0001737 (parathyroid gland), UBERON:0002113 (kidney), UBERON:0001911 (mammary gland)-n/a.

8. Temporal Development

Onset: Congenital genetic lesion with clinical onset in infancy to early childhood — most reported cases present with rachitic signs (bowing, growth failure) and/or alopecia within the first 1–2 years of life; alopecia, when it occurs, is frequently apparent from birth or the first months.

Onset pattern: Insidious/progressive for the skeletal phenotype (worsening over months if undiagnosed), occasionally punctuated by acute hypocalcemic events (seizures/tetany) that can be the presenting acute event prompting diagnosis.

Progression: Without treatment, rachitic bone disease progresses with worsening deformity, growth retardation, and motor disability. With calcium-based treatment (see §12), the skeletal phenotype is generally reversible/healable — radiographic and biochemical normalization documented over roughly 8 weeks to 6 months depending on severity/delay to diagnosis (Frontiers, Saudi Arabia cohort; case reports above). Alopecia, in contrast, is typically stable/persistent and largely treatment-refractory even when the skeletal disease resolves.

Disease course pattern: Chronic but medically manageable — not classically relapsing-remitting, though inadequate treatment adherence can allow biochemical relapse. A 2025 Hormone Research in Paediatrics report specifically notes that persistent hyperparathyroidism can remain despite normalization of hypophosphatemia and radiographic healing of rickets, indicating dissociation between different biochemical/clinical axes during treatment response (Karger 2025; PMC12187100).

Critical periods: Early diagnosis and initiation of high-dose calcium therapy is critical to prevent long-term skeletal deformity and to shorten time-to-healing; delayed diagnosis is explicitly associated with longer treatment courses (up to 6 months of IV calcium in severe/delayed cases per the Saudi cohort).

9. Inheritance and Population

Epidemiology: VDDR2A/HVDRR is an ultra-rare disorder without a well-established global prevalence figure specific to the 2A subtype. The broader category of hypocalcemic vitamin D-dependent rickets (VDDR overall, types 1 and 2) has been estimated in Denmark at approximately 1 in 250,000 children under age 15 (search synthesis, cf. Springer VDDR review); no dedicated Orphanet prevalence class specific to VDDR2A was retrieved in this search (VDDR is grouped under "Hypocalcemic vitamin D-dependent rickets" in Orphanet without a granular 2A-specific number). Given the low observed patient counts in the literature (dominated by single-family/single-case reports across Chinese, Egyptian, Saudi, and other largely consanguineous populations), a prevalence_class of ULTRA_RARE or the Orphanet numeric band BELOW_1_IN_1000000 is a reasonable placeholder pending confirmation from an authoritative source.

Inheritance pattern: Autosomal recessive in the great majority of reported cases (biallelic VDR mutations); rare dominant-negative heterozygous cases have been documented via a distinct molecular mechanism (constitutive corepressor recruitment) (PMC5365159), and at least one atypical single-heterozygous-variant presentation has been reported clinically (PMC12003035) — curators should model both an AR Inheritance block and, where the evidence supports it, a distinct dominant-negative note rather than conflating the two mechanisms.

Penetrance: Effectively complete for the biochemical/skeletal phenotype in biallelic loss-of-function carriers; variable expressivity for alopecia (ranging from absent to total), correlating with the severity/type of the underlying functional VDR defect (ligand-binding vs. DNA-binding vs. dominant-negative).

Genetic anticipation: Not reported/applicable (VDR loss-of-function is not a repeat-expansion disorder).

Germline mosaicism: Not specifically documented in the sources reviewed, though theoretically possible for any autosomal recessive condition; not a prominent feature of the VDDR2A literature.

Founder effects / consanguinity: Strongly relevant — many reported kindreds are from consanguineous populations (Chinese, Egyptian, Middle Eastern/Saudi), and uniparental disomy has been documented as an alternative route to apparent homozygosity without biparental transmission (PMC4496068).

Carrier frequency: Not established/reported in the literature surveyed, consistent with the largely private nature of pathogenic VDR alleles.

Population demographics: No strong sex predilection is reported (autosomal, not X-linked); case series span pediatric populations globally, with concentration of published cohorts in the Middle East/North Africa and East Asia, likely reflecting both true prevalence (consanguinity rates) and reporting/ascertainment patterns.

10. Diagnostics

Core laboratory pattern: Hypocalcemia, hypophosphatemia (though may be absent — see atypical presentations), elevated alkaline phosphatase, elevated PTH (secondary hyperparathyroidism), and the key discriminating test: markedly elevated (not low) serum 1,25-dihydroxyvitamin D, which distinguishes VDDR2A from VDDR1A (CYP27B1 defect, low 1,25(OH)₂D) and from nutritional vitamin D deficiency (low 25-OH-D, low/normal 1,25(OH)₂D).

Imaging: Plain radiographs showing classic rachitic changes — metaphyseal widening/fraying/cupping, growth plate widening, long-bone bowing (genu varum), demineralization — used both for diagnosis and to monitor healing response to treatment.

Genetic testing: VDR sequence analysis (single-gene sequencing or inclusion in a rickets/metabolic bone disease gene panel, or exome sequencing) is the definitive diagnostic step, especially important because hypophosphatemia-predominant presentations can be clinically indistinguishable from FGF23-mediated hypophosphatemic rickets without genetic confirmation (Karger 2025). Whole-exome sequencing has been used successfully to identify novel homozygous pathogenic VDR variants (e.g., R343C) in atypical presentations (JCEM Case Reports 2024).

Differential diagnosis: - VDDR1A (CYP27B1 biosynthetic defect): low 1,25(OH)₂D (vs. elevated in VDDR2A), elevated PTH in both. - VDDR1B (CYP2R1 defect — 25-hydroxylase deficiency). - VDDR2B (normal VDR gene/protein; end-organ resistance instead caused by a nuclear ribonucleoprotein that interferes with VDR-DNA interaction — phenotypically similar to 2A but with an intact receptor gene) (OMIM 277440). - Nutritional (vitamin D deficiency) rickets — distinguished by low 25-OH-D. - FGF23-mediated hereditary hypophosphatemic rickets (e.g., XLH/PHEX) — an important pitfall because VDDR2A can present with isolated hypophosphatemia without hypocalcemia, mimicking this category; genetic testing is required to discriminate (JCEM Case Reports 2024; PMC12187100).

Screening: No population newborn-screening program targets VDDR2A specifically, given its rarity; diagnosis relies on clinical suspicion (rickets ± alopecia with markedly elevated 1,25(OH)₂D) followed by targeted or exome genetic testing. Cascade/carrier testing within affected consanguineous families is appropriate once a familial pathogenic variant is identified.

11. Outcome/Prognosis

Mortality: Not associated with increased mortality when appropriately diagnosed and treated with calcium repletion; severe untreated hypocalcemia can produce life-threatening seizures/tetany acutely, but chronic mortality data specific to VDDR2A were not identified in this literature review — the disorder is generally considered manageable rather than lethal.

Morbidity/functional outcome: With prompt, adequately dosed calcium therapy, rickets is fully radiographically and biochemically reversible — documented cases show return to normal ambulation within weeks and complete radiographic healing within ~3 months to 6 months depending on delay-to-diagnosis and severity. Persistent secondary hyperparathyroidism can, however, remain elevated even after phosphate/rickets normalization, per a 2025 Hormone Research in Paediatrics report (Karger 2025) — an important point for long-term monitoring guidance.

Alopecia prognosis: Generally persistent/refractory to treatment — patients with alopecia tend to have more severe underlying receptor dysfunction and respond less well to vitamin D metabolite therapy overall, often requiring the more aggressive calcium-infusion regimens (PMC3196847). Some case reports document partial or full resolution of alopecia with conventional-dose 1α-hydroxycholecalciferol plus oral calcium in milder genotypes (PubMed 21118628), indicating genotype-dependent variability rather than a uniformly fixed outcome.

Prognostic factors: Presence/severity of alopecia (marker of more severe VDR dysfunction and poorer response to vitamin D-based therapy), timeliness of diagnosis (delayed diagnosis associated with longer treatment courses), and specific mutation type (ligand-binding-domain vs. DNA-binding-domain vs. dominant-negative mutations differ in residual receptor function and thus treatment responsiveness).

12. Treatment

First-line strategy — bypass the receptor defect with calcium, not vitamin D metabolites. Because the fundamental lesion is receptor unresponsiveness rather than ligand deficiency, simply increasing vitamin D or calcitriol dosing is often ineffective; the mainstay of therapy is high-dose calcium supplementation, sufficient to drive passive (non-VDR-dependent, paracellular) intestinal calcium absorption:

• Mild-to-moderate cases: managed with high-dose oral calcitriol plus supplemental oral calcium (case-based review; PubMed 7833085 — oral calcium treatment in VDDR type II).
• Severe/alopecic/treatment-refractory cases: require intravenous (IV) calcium infusion, shown to be more potent/effective than oral therapy for rapid clinical, radiological, and biochemical improvement. Reported protocols include daily calcium gluconate infusion (e.g., 250 mg elemental calcium every 8 hours, several days per week) continued until calcium/phosphate normalize — typically averaging 8 weeks, up to 6 months in severe/delayed-diagnosis cases (Frontiers, Saudi Arabia cohort). Documented outcomes include return to independent ambulation within ~2 weeks and complete radiographic healing by ~3 months.
• An adult-onset case documented favorable changes in bone metabolic parameters following oral calcium supplementation (PubMed 28367941).

Pharmacotherapy — vitamin D analogs: High-dose active vitamin D metabolites (calcitriol, 1α-hydroxycholecalciferol/alfacalcidol) are used adjunctively, particularly in milder genotypes, and can improve both rickets and (in some reports) alopecia (PubMed 21118628). Suggested NCIT term: NCIT:C15986 (Pharmacotherapy) with therapeutic_agent bound to CHEBI calcitriol (CHEBI:17823) or alfacalcidol.

Alopecia-directed/experimental approaches: - Because alopecia in VDR-null models arises from a ligand-independent VDR function in keratinocytes, systemic calcitriol/calcium therapy does not reliably restore hair growth; topical calcipotriol (a vitamin D analog with reduced calcemic activity, used for its VDR-binding/epidermal-differentiation effects independent of systemic calcium metabolism) has been explored for alopecia areata and is mechanistically relevant here, though robust VDDR2A-specific efficacy data are limited (Ann Dermatol / calcipotriol review). - Gene-therapy proof-of-concept: a VDR-expressing adenoviral vector has been used experimentally to treat alopecia in a rat model of type II rickets, restoring hair-follicle VDR expression (PMC10613246) — MODEL_ORGANISM evidence, not yet a human therapy. - Note: seocalcitol (EB1089) and related low-calcemic vitamin D analogs are primarily investigated as anticancer agents (pancreatic, hepatocellular, CLL) rather than as VDDR2A treatments specifically — relevant mainly as background on structure-activity of VDR ligands, not a direct VDDR2A therapeutic (BJC EB1089 pancreatic cancer trial).

Surgical/orthopedic: Corrective orthopedic surgery may be required for severe or fixed long-bone deformity in cases with delayed diagnosis/treatment, though this is supportive rather than disease-modifying (suggested NCIT C16186, Orthopedic Surgical Procedure).

Supportive care: Physical therapy/rehabilitation (NCIT:C15302) to address motor delay from rachitic myopathy/deformity during and after biochemical treatment.

Monitoring: Serial calcium, phosphate, alkaline phosphatase, and PTH; per the 2025 Karger report, PTH may remain persistently elevated despite normalization of phosphate and radiographic healing, so PTH cannot be used alone as a marker of complete treatment response (Karger 2025).

Experimental/clinical trials: No VDDR2A-specific registered interventional trials were identified in this search; management is derived from case-report-level and small single-center retrospective evidence, not randomized trial data.

13. Prevention

Primary prevention: Not applicable in the classic sense (this is a fully penetrant Mendelian genetic disorder) — the relevant "primary prevention" tool is genetic counseling and carrier/prenatal testing in consanguineous families or families with a known proband, given the autosomal recessive (occasionally dominant-negative) inheritance.

Secondary prevention (early detection): Prompt clinical suspicion (rickets with elevated, not low, 1,25(OH)₂D; ± alopecia) and early genetic confirmation are the practical "secondary prevention" tools that shorten time-to-treatment and reduce the risk of severe/fixed skeletal deformity.

Tertiary prevention: Adequate ongoing calcium supplementation and monitoring to prevent recurrence of hypocalcemic crises and to protect against long-term skeletal deformity and growth impairment; monitoring for persistent hyperparathyroidism as a residual complication even after apparent rickets healing.

Genetic counseling: Recommended for parents of an affected child (autosomal recessive recurrence risk ~25% per pregnancy for the typical biallelic form) and for extended family members in consanguineous kindreds; prenatal or preimplantation testing is technically feasible once the familial pathogenic VDR variant(s) are known, though this was not specifically documented as routine practice in the sources reviewed.

Public health/behavioral: General population-level vitamin D/calcium sufficiency programs (e.g., sunlight exposure guidance, dietary fortification) address nutritional rickets but have no bearing on the genetic VDR-resistance mechanism underlying VDDR2A specifically.

14. Other Species / Natural Disease

No naturally occurring VDDR2A/HVDRR case in a non-human companion-animal or wildlife species (i.e., a spontaneous VDR-null phenotype analogous to human disease) was identified in this search; the available cross-species data are from engineered rodent models (see §15) rather than naturally occurring veterinary disease. Curators should check OMIA (Online Mendelian Inheritance in Animals) directly if a naturally occurring animal correlate is needed for the entry, as this was not surfaced by the searches performed here.

15. Model Organisms

VDR knockout (Vdr⁻/⁻) mouse: The primary and best-characterized animal model. Targeted ablation of VDR produces a mouse model that recapitulates the core human VDDR2A phenotype: mice are normal at birth but develop growth retardation, hypocalcemia, hyperparathyroidism, rickets, osteomalacia, and alopecia — closely mirroring human VDDR2A with alopecia (PNAS 94(18):9831; JCI 11676; PubMed 22903507 — physiological insights review). - Fidelity: High for the skeletal/mineral-metabolism phenotype (RECAPITULATES) and for alopecia (RECAPITULATES) — the mouse model directly established that alopecia results from defective anagen (hair growth phase) initiation and demonstrated the ligand-independent role of VDR in hair-follicle keratinocytes (a keratinocyte-specific VDR transgene with a ligand-binding-abolishing mutation still restores normal hair cycling in VDR-null mice) (Oxford Mol Endocrinol 19(4):855; PNAS 0702884104). - Limitation: Because the alopecia-preventing VDR function is ligand-independent, this model demonstrates that vitamin D/calcitriol-based pharmacotherapy is mechanistically unlikely to reverse alopecia — a translational insight directly informing human treatment expectations (§12).

Humanized VDR mouse models: A "humanized" mouse model of HVDRR without alopecia has been engineered, allowing dissociation of the rachitic/mineral phenotype from the alopecia phenotype and enabling study of genotype-phenotype correlation for specific human VDR mutations (PubMed 25147982; Endocrinology 155(11):4137).

Rat model: A rat model of "type II rickets" with alopecia has been used as a preclinical platform for VDR gene-therapy proof-of-concept (adenoviral VDR-expressing vector) targeting the alopecia phenotype specifically (PMC10613246).

Applications: These rodent models have been used to (1) establish the causal relationship between VDR loss and both the mineral/skeletal phenotype and alopecia, (2) dissect ligand-dependent (mineral metabolism) versus ligand-independent (hair cycle) VDR functions, (3) test genotype-specific functional consequences of human VDR mutations via "humanized" knock-in approaches, and (4) pilot gene-replacement therapeutic strategies for the alopecia arm of the disease.

Suggested NCBITaxon terms: NCBITaxon:10090 (Mus musculus), NCBITaxon:10116 (Rattus norvegicus).

Summary of Key PMIDs/Sources for Curation

Note on evidence-source classification for curation: Case reports/series (majority of citations above) = HUMAN_CLINICAL; VDR-null mouse/rat and humanized-mouse studies = MODEL_ORGANISM; in-vitro transactivation/reporter-gene assays of specific VDR mutants = IN_VITRO. No COMPUTATIONAL-only evidence was identified as primary support for any major claim in this report.

Sources: - Entry - #277440 - VITAMIN D-DEPENDENT RICKETS, TYPE 2A; VDDR2A - OMIM - Entry - *601769 - VITAMIN D RECEPTOR; VDR - OMIM - vitamin D-dependent rickets, type 2A - NORD - Heterozygous Hereditary Vitamin D-Dependent Rickets Type 2A (VDDR2A) in a Patient Presenting With Pseudoarthrosis - PMC - Novel Vitamin D Receptor Mutations in Hereditary Vitamin D Resistant Rickets in Chinese - PMC - The Role of Vitamin D Receptor Mutations in the Development of Alopecia - PMC - Compound heterozygous mutations in the vitamin D receptor in a patient with hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia - PubMed - Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from a novel missense mutation in the DNA-binding domain of the vitamin D receptor - PMC - Hereditary vitamin D resistant rickets: novel splice site mutation, oral calcium therapy - ScienceDirect - Functional Analysis of VDR Gene Mutation R343H - PMC - Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia in four Egyptian families - PubMed - Case of vitamin D–dependent rickets type 2A presenting with hypophosphatemia without hypocalcemia - JCEM Case Reports - Persistent Hyperparathyroidism in Vitamin D-Dependent Rickets Type 2A - PMC - Persistent Hyperparathyroidism in Vitamin D-Dependent Rickets Type 2A - Karger - Clinical characteristics and long-term management for VDDR type II - Saudi Arabia cohort - Frontiers - Oral calcium treatment in vitamin D-dependent rickets type II - PubMed - Changes in bone metabolic parameters following oral calcium supplementation - PubMed - Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) caused by a VDR mutation: novel mechanism of dominant inheritance - PMC - Hereditary 1,25-dihydroxyvitamin D resistant rickets due to a mutation causing multiple defects in VDR function - PubMed - Detection of Hereditary 1,25-Hydroxyvitamin D-Resistant Rickets Caused by Uniparental Disomy of Chromosome 12 - PMC - VDR gene - GeneCards - Vitamin D Dependent Rickets 2A With Alopecia: Three Cases With Novel Genetic Variants - PubMed - Heterozygous Hereditary Vitamin D‐Dependent Rickets Type 2A (VDDR2A) in a Patient Presenting With Pseudoarthrosis - Wiley - Novel VDR gene mutation in a VDDR2A compound heterozygote - Endocrine Abstracts - Vitamin D dependent rickets type 2A in a 1-year-old girl - Endocrine Abstracts - JCI - Metabolic and cellular analysis of alopecia in vitamin D receptor knockout mice - A humanized mouse model of hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia - PubMed - Humanized Mouse Model of HVDRR Without Alopecia - Oxford Academic - Physiological insights from the vitamin D receptor knockout mouse - PubMed - Targeted ablation of the vitamin D receptor: An animal model of VDDR type II with alopecia - PNAS - Gene therapy for alopecia in type II rickets model rats using VDR-expressing adenovirus vector - PMC - The role of vitamin D receptor signaling in hair follicle health and alopecia - PMC - Vitamin D receptor is essential for normal keratinocyte stem cell function - PNAS - Ligand-Independent Actions of the Vitamin D Receptor Maintain Hair Follicle Homeostasis - Oxford Academic - Ligand-Independent Vitamin D Receptor Actions Essential for Keratinocyte Homeostasis - PMC - Retinoid X Receptor Is a Nonsilent Major Contributor to VDR-Mediated Transcriptional Activation - Oxford Academic - DNA binding alters coactivator interaction surfaces of the intact VDR–RXR complex - PMC - Relationship of Structure and Function of DNA-Binding Domain in Vitamin D Receptor - PMC - Vitamin D Hydroxylation-Deficient Rickets (VDDR) – Types 1A, 1B, 2A, 2B - Springer - Orphanet: Hypocalcemic vitamin D-dependent rickets - Vitamin D-dependent rickets, type 2 - NIH GTR - Vitamin D-dependent rickets type II with alopecia - NIH GTR - A phase II trial of seocalcitol (EB1089) in inoperable pancreatic cancer - British Journal of Cancer - Alopecia in vitamin D-dependent rickets type II responding to 1α-hydroxycholecalciferol - PubMed

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

• DOI:10.1159/000546444/927170/Persistent-Hyperparathyroidism-in-Vitamin-D (6 mentions) - Identifier did not resolve to a record